Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications

Cancer Treatment and Research Communications(2023)10.1016/j.ctarc.2023.100779Source: DataRank Database

Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications is a research paper published in Cancer Treatment and Research Communications (2023). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.28)OA: goldTopics (32)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Kathryn H. Gessner ORCID,Alysen Demzik,Elizabeth Moreton ORCID,William Y. Kim ORCID,Sara E. Wobker ORCID

Live enrichment

PubMed:37988935 PMC:PMC11315140 OpenAlex:https://openalex.org/W4388776312

National Cancer Institute

Grant: 1K08CA248967-01

Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer

NIH

Grant: T32-CA244125

NCI NIH HHS

Grant: K08 CA248967

NCI NIH HHS

Grant: T32 CA244125

National Institutes of Health

Grant: 5T32CA244125-02

UNC Integrated Translational Oncology Program (UNC-iTOP)

FWCI

2.28

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ctarc.2023.100779

publisherhttps://doi.org/10.1016/j.ctarc.2023.100779

publisherhttps://api.elsevier.com/content/article/PII:S2468294223001016?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2468294223001016?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37988935

Fields of Study

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesFerroptosis and cancer prognosis03 medical and health sciences0302 clinical medicine

MeSH Terms

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansGenomics

Keywords

Bladder cancerPersonalized medicineCancerGenomicsDiseaseBiologyComputational biologyUrothelial carcinomaBioinformaticsCancer researchMedicineInternal medicineGenomeGeneGeneticsMolecular characterizationPlasmacytoidCarcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasms. Tumors. Oncology. Including cancer and carcinogensHumansRC254-282Article

Sustainable Development Goals

SDG 0: Good health and well-being